Natural and modified IL-2 for the treatment of cancer and autoimmune diseases
- 1 September 2019
- journal article
- research article
- Published by Elsevier in Clinical Immunology
- Vol. 206, 63-70
Abstract
No abstract availableKeywords
Funding Information
- Japan Society for the Promotion of Science (JP17K10001)
This publication has 82 references indexed in Scilit:
- Foxp3+Regulatory T Cells in Mouse Models of Type 1 DiabetesJournal of Diabetes Research, 2013
- Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’Nature, 2012
- Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupusProceedings of the National Academy of Sciences, 2009
- A Low Interleukin-2 Receptor Signaling Threshold Supports the Development and Homeostasis of T Regulatory CellsImmunity, 2009
- Central Role of Defective Interleukin-2 Production in the Triggering of Islet Autoimmune DestructionImmunity, 2008
- Interleukin 2: from immunostimulation to immunoregulation and back againEMBO Reports, 2007
- Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunityNature Genetics, 2007
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- Adoptive immunotherapy for cancer: building on successNature Reviews Immunology, 2006
- lnterleukin-2 programs mouse αβ T lymphocytes for apoptosisNature, 1991